AQR Capital Management, LLC and AQR Capital Management Holdings, LLC filed Amendment No. 2 to Schedule 13G with the SEC on November 13, 2026, disclosing their beneficial ownership of common stock in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) as of September 30, 2026.
Key Highlights
- Aggregate beneficial ownership: Both AQR entities each report 1,386,343 shares of Sarepta Therapeutics common stock beneficially owned.
- Percent of class: The reported holdings represent 1.31% of the outstanding class of common stock.
- Convertible Notes included: According to the filing, the reported amount includes Convertible Notes representing 990,669 shares of Common Stock, $0.0001 par value per share.
- Voting and dispositive power: Both entities report zero sole voting or sole dispositive power; shared voting power and shared dispositive power are each listed as 1,386,343 shares.
- Relationship between filers: AQR Capital Management, LLC is described in the filing as a wholly owned subsidiary of AQR Capital Management Holdings, LLC.
- Event date: The date of event requiring this filing is stated as September 30, 2026.
AQR's Amended Sarepta Therapeutics Position as of September 30, 2026
According to the filing, AQR Capital Management, LLC, an investment adviser organized in the United States, and its parent holding company AQR Capital Management Holdings, LLC, jointly filed Amendment No. 2 to Schedule 13G covering their holdings in Sarepta Therapeutics, Inc. common stock, par value $0.0001 per share (CUSIP 803607100). Both entities are headquartered at One Greenwich Plaza, Suite 130, Greenwich, Connecticut 06830. The filing was signed by Henry Parkin as Authorized Signatory for both entities on November 13, 2026.
The filing discloses that the aggregate amount beneficially owned by each reporting person is 1,386,343 shares, representing 1.31% of the class. The filing further specifies that this total includes Convertible Notes representing 990,669 shares of common stock. Neither entity holds sole voting or sole dispositive power over any shares; all voting and dispositive power is reported as shared, at 1,386,343 shares each.
The filing indicates that Item 5 applies, confirming ownership of 5 percent or less of the class. The certification included in the filing states that "the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities."
What Was Disclosed
AQR Capital Management, LLC and AQR Capital Management Holdings, LLC disclosed in Amendment No. 2 to Schedule 13G that they beneficially own 1,386,343 shares of Sarepta Therapeutics common stock, equal to 1.31% of the class, as of September 30, 2026, including holdings via Convertible Notes.



Please wait processing your request...